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Every scientist’s nightmare is betting
everything on an experiment that will
take unheard-of investment and well
over a decade to complete — only to
have a Johnny-come-lately stride in
midway through the work and
declare that he’s going to beat you to
the finish by years. The ‘J.’ in J. Craig
Venter may not stand for ‘Johnny’,
but the rest of the bad dream is
happening to Francis Collins and the
Human Genome Project, if you
believe the news reports.
“A pioneer in genetic sequencing
and a private company are joining
forces with the aim of deciphering
the entire DNA, or genome, of
humans within three years, faster and
cheaper than the federal government
is planning,” Nicholas Wade wrote in
the 10 May edition of the New York
Times. And indeed, the report
suggested that Collins and his boss,
NIH director Harold Varmus were
throwing in the towel. “Both Dr
Varmus and Dr Collins expressed
confidence that they could persuade
Congress to accept the need for
[refocusing the $3 billion NIH
effort]… noting that the sequencing
of mouse and other genomes has
always been included as a necessary
part of the human genome project.”
In fact, Collins and Varmus were
not about to give up on the project,
even though Venter’s plan does
indeed present a formidable
challenge. On 15 September, Collins
announced that he is planning to
match Venter’s 2001 deadline for a
rough map — and keep going from
there, to make a more accurate and
complete map by 2003.
This adventure makes for great
story-telling. Here’s a man with a
million-dollar yacht and an ego to
match — and an impressive intellect,
to be sure. In the best American
tradition, he’s the little guy taking on
the government. And there’s some
bile, to boot, such as when Venter
calls Collins a “Government
bureaucrat whose job is to hand out
money to help get the genome done,”
in a New York Times Magazine profile of
the personality du jour. “[I]t was as if
some aerospace executive had vowed
in the mid-1960s to overtake NASA
and be the first to put humans on
the moon,” the Baltimore Sun noted.
Time magazine, among others,
compared Venter with Bill Gates,
saying that he “may someday control
information about the human
genome — which in effect is the
operating system of humans.”
“If there is a gene for causing
uproar, you can bet Craig Venter
has it”
Just what Venter proposed to do was a
bit more vague. Most news accounts
quoted critics noting that Venter’s
map of the human genome would
contain some gaps, and that his
process was riskier than the one being
put to use by the Human Genome
Project. Accounts usually left the
reader to guess what that meant,
though Science News, for one, spelled it
out nicely, explaining how Venter’s
shotgun approach involves “shattering
an organism’s DNA” and then trying
to piece the fragments back together
by comparing their ends. “People
have felt that you might gather all
that data and not be able to assemble
it… it takes faith,” Frederick Blattner
of the University of Wisconsin-
Madison told Science News. Writer
John Travis went on to explain the
more methodical approach of the
NIH, so readers could understand the
more widely quoted cautions voiced
by Collins, Maynard Olson at the
University of Washington and others.
By and large, the US press played
this story as a race, involving egos as
well as megabucks. (A surprising
number of reports were in the
business pages.) Ventures into the
broader social realms were fairly
tepid, such as the Washington Post
editorial that said Venter’s plan
“raises intriguing public questions”
such as “public access to patented
gene sequences… the ease with
which these genes are patented…
and the rights… of individuals whose
specific genes turn out to form the
basis for lucrative inventions.”
Newspapers overseas were
considerably less genteel. “A struggle
of Darwinian proportions is taking
place in the scientific community
over a plan by an American company
to rapidly sequence the human
genome and patent some genes,”
wrote the Canberra Times. Europeans
were debating the ethics of patenting
genes when the story broke, so
Venter’s plan played right in. “If
there is a gene for causing uproar,”
wrote Robin McKie of The Observer,
“you can bet Craig Venter has it.
More important, though, you can also
be sure he is the man most likely to
isolate it. In the predatory world of
biotechnology, Venter… is now
regarded as the deadliest member of
a breed of research raptors who hunt
down genes for cash.”
McKie seemed a bit vague on just
how Venter plans to cash in on these
genes, referring to Venter’s partner —
instrument maker Perkin-Elmer — as
a “pharmaceutical giant,” but the
article reflected a much higher index
of suspicion than is evident in the US
press. After all, to Americans who
have grown up with Genentech, this
is just another company out to cash in
on gene discoveries. And if you
believe the folks at Incyte
Pharmaceuticals in Palo Alto
California, they’re going to sequence
all the really juicy genes while J. Craig
Venter is still deciding whether to set
the Genoa or the spinnaker — which
the New York Times says is adorned
with a 20-foot picture of himself — on
his dead run back from Bermuda.
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